An Overview of Aducanumab for the Treatment of Alzheimer Disease

Video

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

In a recent interview with Pharmacy Times, Pamela Spicer, senior analyst with Datamonitor Healthcare at Informa Pharma Intelligence, reviewed the approval of aducanumab and what pharmacists should know about its use in patients with Alzheimer disease. Spicer said aducanumab is a once-monthly infusion with a 6-month titration schedule. It has several notable adverse effects, including amyloid-related imaging abnormalities which should be monitored closely.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.